Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | PPARG | P37231 | 9/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335722 | 0.93 | PPARD (0.61) | PPARDCYP2C9PPARGPPARANPC1 | |
| SCHEMBL334781 | 0.92 | PPARD (0.56) | PPARDCYP2C9PPARGPPARANPC1 | |
| SCHEMBL10220339 | 0.86 | PPARD (0.61) | PPARDCYP2C9PPARGPPARANPC1 | |
| SCHEMBL10220118 | 0.85 | PPARD (0.53) | PPARDCYP2C9PPARGPPARANPC1 | |
| SCHEMBL334157 | 0.84 | NPC1 (0.54) | PPARDCYP2C9PPARGNPC1RAB9A | |
| SCHEMBL10219493 | 0.84 | PPARD (0.52) | PPARDCYP2C9PPARGPPARANPC1 | |
| SCHEMBL335656 | 0.82 | NPC1 (0.59) | PPARDPPARGPPARANPC1RAB9A | |
| SCHEMBL334248 | 0.81 | PPARD (0.57) | PPARDCYP2C9PPARGPPARANPC1 | |
| SCHEMBL27727345 | 0.81 | NPC1 (0.53) | PPARDCYP2C9PPARGPPARANPC1 | |
| SCHEMBL335857 | 0.80 | NPC1 (0.55) | PPARDCYP2C9PPARGPPARANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885CYP2C9 163/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.